Helen Kotanides

Actinium Pharmaceuticals (United States) — United States

Medicine · Health Sciences

13h-index1.5kcitations61works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(26), Monoclonal and Polyclonal Antibodies Research(26), Immunotherapy and Immune Responses(19), Cancer Cells and Metastasis(11), Immune Cell Function and Interaction(11)

Publications61 total

Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML
Blood·2024
Abstract A149: Characterization of HER3 targeted radioligand therapy using molecular imaging
Molecular Cancer Therapeutics·2023
Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner
Blood·2023· 5 cited
1166 Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells
Regular and Young Investigator Award Abstracts·2023Open Access
AML-502 Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: AML-502 Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML
Clinical Lymphoma Myeloma & Leukemia·2023
Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers.
Journal of Clinical Oncology·2023
Abstract 5040: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors
Cancer Research·2023· 2 cited
Abstract 4421: Targeting myeloid-derived suppressor cells with actinium-225 lintuzumab, a CD33 antibody radioconjugate to enhance antitumor immunity
Cancer Research·2023
Data from Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
2023Open Access
Supplementary Data File from Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
2023Open Access
Data from Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
2023Open Access
Supplementary Data File from Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
2023Open Access
Figure S8 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Figure S6 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Figure S9 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Figure S3 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Supplementary Materials and Methods from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Table S1 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
Supplementary Materials and Methods from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Dale L. Ludwig(28), David Surguladze(27), Carmine Carpenito(25), Ivan Inigo(25), Anthony L. Pennello(25), Xinlei Chen(25), Darin Chin(25), Andreas Sonyi(25), Jaafar N. Haidar(25), Ruslan D. Novosiadly(25), Gregory D. Plowman(25), Michael Kalos(25), Maria B. Lebron(23), Douglas Burtrum(23), Michael J. Topper(23), Rose Marie Sattler(21), Juqun Shen(21), Jingxing Li(21), Leyi Shen(21), Amélie Forest(21)